Once-daily darunavir/ritonavir and abacavir/lamivudine versus tenofovir/emtricitabine for treatment-naïve patients with a baseline viral load of more than 100000copies/ml

Nishijima, Takeshia,b; Komatsu, Hirokazuc; Teruya, Katsujia; Tanuma, Junkoa; Tsukada, Kunihisaa; Gatanaga, Hiroyukia,b; Kikuchi, Yoshimia; Oka, Shinichia,b

doi: 10.1097/QAD.0b013e32835cadb7
Research Letters

The efficacy and safety of fixed-dose abacavir/lamivudine against tenofovir/emtricitabine, both with once-daily darunavir/ritonavir, was examined in 80 treatment-naïve patients with a baseline HIV-1 viral load of more than 100 000 copies/ml. The time to virologic failure by 48 weeks was not different between the two groups. The percentage of patients with viral suppression was not significantly different with per protocol population. Tenofovir/emtricitabine showed better tolerability; more patients on abacavir/lamivudine changed regimen than those on tenofovir/emtricitabine. A randomized trial to elucidate the efficacy and safety of these two regimens is warranted.

aAIDS Clinical Center, National Center for Global Health and Medicine, Tokyo

bCenter for AIDS Research, Kumamoto University, Kumamoto

cDepartment of Community Care, Saku Central Hospital, Nagano, Japan.

Correspondence to Hiroyuki Gatanaga, MD, PhD, AIDS Clinical Center, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku, Tokyo 162-0052, Japan. Tel: +81 3 3202 7181; fax: +81 3 5273 6483; e-mail: higatana@acc.ncgm.go.jp

Received 23 July, 2012

Revised 31 October, 2012

Accepted 15 November, 2012

© 2013 Lippincott Williams & Wilkins, Inc.